ONCOGENEX PHARMACEUTICALS IN's ticker is OGXI and the CUSIP is 68230A106. A total of 27 filers reported holding ONCOGENEX PHARMACEUTICALS IN in Q2 2017. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2017 | $5,000 | +150.0% | 15,154 | +195.1% | 0.00% | – |
Q1 2017 | $2,000 | -33.3% | 5,135 | -7.1% | 0.00% | – |
Q4 2016 | $3,000 | 0.0% | 5,525 | -6.8% | 0.00% | – |
Q3 2016 | $3,000 | -40.0% | 5,925 | +3.5% | 0.00% | – |
Q2 2016 | $5,000 | +150.0% | 5,725 | +97.4% | 0.00% | – |
Q1 2016 | $2,000 | -50.0% | 2,900 | 0.0% | 0.00% | – |
Q4 2015 | $4,000 | -85.2% | 2,900 | -76.4% | 0.00% | – |
Q3 2015 | $27,000 | -60.9% | 12,270 | -58.7% | 0.00% | – |
Q2 2015 | $69,000 | +7.8% | 29,740 | -0.3% | 0.00% | – |
Q1 2015 | $64,000 | +326.7% | 29,840 | +335.6% | 0.00% | – |
Q4 2014 | $15,000 | -28.6% | 6,850 | -8.0% | 0.00% | – |
Q3 2014 | $21,000 | -34.4% | 7,448 | -12.9% | 0.00% | – |
Q2 2014 | $32,000 | -95.1% | 8,550 | -84.5% | 0.00% | – |
Q1 2014 | $649,000 | +19.3% | 55,225 | -15.5% | 0.00% | – |
Q4 2013 | $544,000 | -23.7% | 65,335 | -15.1% | 0.00% | -100.0% |
Q3 2013 | $713,000 | +4.5% | 76,961 | +10.6% | 0.00% | 0.0% |
Q2 2013 | $682,000 | – | 69,560 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
GREAT POINT PARTNERS LLC | 2,111,590 | $7,876,000 | 3.50% |
Abingworth LLP | 603,740 | $2,234,000 | 1.04% |
BVF INC/IL | 862,069 | $3,216,000 | 0.51% |
SABBY MANAGEMENT, LLC | 922,562 | $3,441,000 | 0.15% |
TFS CAPITAL LLC | 360,260 | $1,344,000 | 0.11% |
BOGLE INVESTMENT MANAGEMENT L P /DE/ | 175,980 | $656,000 | 0.04% |
Tekla Capital Management LLC | 113,100 | $422,000 | 0.04% |
Visium Asset Management, LP | 598,443 | $2,232,000 | 0.04% |
A.R.T. Advisors, LLC | 101,905 | $380,000 | 0.02% |
B. Riley Wealth Management, Inc. | 6,300 | $23,000 | 0.02% |